The goal of Histogenics (NasdaqGM: HSGX) is to become a leading regenerative medicine company developing, marketing and commercializing products in the musculoskeletal segment of the marketplace. The company plans to build its core technology platform as well as expand its clinical products’ therapeutic applications to develop new and innovative solutions. Histogenics leverages a combination of the latest advances in molecular biology and proprietary materials sciences to create products designed to help improve patient outcomes. The company’s regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The company’s first product candidate, NeoCart, leverages its platform to provide an innovative treatment in the orthopaedic space, specifically cartilage damage in the knee. NeoCart is currently enrolling a Phase 3 clinical trial in the United States under a Special Protocol Assessment (SPA).
Histogenics had its initial public offering December 3, 2014.